Shared on 01 Nov 25
Analysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.
Shared on 18 Oct 25
Analysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.
Shared on 03 Oct 25
Fair value Decreased 9.21%Analysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 3.74%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 18%AnalystConsensusTarget has decreased future PE multiple from 55.4x to 43.0x.
Shared on 02 Apr 25
Fair value Decreased 0.27%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 101%AnalystConsensusTarget has increased revenue growth from 10.2% to 17.3%, decreased profit margin from 20.4% to 18.2% and increased future PE multiple from 41.8x to 55.4x.